Cytophage Technologies (TSXV:CYTO) EV-to-EBIT : 10.67 (As of May. 29, 2024)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cytophage Technologies's Enterprise Value is C$23.76 Mil. Cytophage Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$2.23 Mil. Therefore, Cytophage Technologies's EV-to-EBIT for today is 10.67.

The historical rank and industry rank for Cytophage Technologies's EV-to-EBIT or its related term are showing as below:

TSXV:CYTO' s EV-to-EBIT Range Over the Past 10 Years
Min: -17.49 Med: 0 Max: 12.84
Current: 10.67

During the past 3 years, the highest EV-to-EBIT of Cytophage Technologies was 12.84. The lowest was -17.49. And the median was 0.00.

TSXV:CYTO's EV-to-EBIT is ranked worse than
52.71% of 425 companies
in the Biotechnology industry
Industry Median: 9.85 vs TSXV:CYTO: 10.67

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cytophage Technologies's Enterprise Value for the quarter that ended in Dec. 2023 was C$0.00 Mil. Cytophage Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$2.23 Mil. Cytophage Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was %.

Cytophage Technologies EV-to-EBIT Historical Data

The historical data trend for Cytophage Technologies's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies EV-to-EBIT Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

EV-to-EBIT

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
EV-to-EBIT	-	-	-	-	-

Competitive Comparison of Cytophage Technologies's EV-to-EBIT

For the Biotechnology subindustry, Cytophage Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytophage Technologies's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's EV-to-EBIT falls into.

Cytophage Technologies EV-to-EBIT Calculation

Cytophage Technologies's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	23.755	/	2.227
	=	10.67

Cytophage Technologies's current Enterprise Value is C$23.76 Mil.
Cytophage Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$2.23 Mil.

Cytophage Technologies (TSXV:CYTO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cytophage Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	2.227	/	0
	=	%

Cytophage Technologies's Enterprise Value for the quarter that ended in Dec. 2023 was C$0.00 Mil.
Cytophage Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$2.23 Mil.

Cytophage Technologies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.